LONDON, UK / ACCESSWIRE / August 14, 2017 / Pro-Trader Daily takes a closer look at Amgen Inc. (NASDAQ: AMGN) as the Company's stock will begin trading ex-dividend on August 15, 2017. In order to capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on August 14, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on AMGN. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=AMGN

Dividend Declared

On July 28, 2017, Amgen announced that its Board of Directors declared a $1.15 per share dividend for the third quarter of 2017. The dividend will be paid on September 08, 2017, to all stockholders of record as of the close of business on August 17, 2017.

Amgen's indicated dividend represents a yield of 2.71%, which is more than four times the average dividend yield of 0.65% for the Healthcare sector. The Company has raised its dividend for 6 consecutive years.

Dividend Insights

Amgen has a dividend payout ratio of 36.8%, which means that the Company distributes approximately $0.37 for every $1.00 earned. The dividend payout ratio reflects how much money a company is returning to shareholders, versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts' estimates, Amgen is forecasted to report earnings of $12.80 for the upcoming year which is approximately above the Company's annualized dividend of $4.60.

Amgen generated $2.1 billion of free cash flow in Q2 2017 versus $2.5 billion in the second quarter of 2016, the difference driven by the timing of tax payments. The Company's second quarter 2017 dividend of $1.15 per share was paid on June 08, 2017, a 15% increase versus Q2 2016. As of June 30, 2017, the Company had cash, cash equivalents, and marketable securities worth $39.23 billion compared to cash of $38.09 billion as on December 31, 2016. The Company's current assets were $48.44 billion. The strong financial position indicates the Company's ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development about Amgen

On August 08, 2017, the Scottish Medicines Consortium (SMC) has published its advice accepting the use of Amgen's Multiple Myeloma Treatment, KYPROLIS (carfilzomib) in combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The advice takes into account the continuing availability of the Patient Access Scheme (PAS) agreed or a list price that is equivalent or lower.

The SMC advice guides NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on the use of carfilzomib within NHS Scotland. It has taken into account the views of patient group representatives and clinical specialists in a Patient and Clinical Engagement (PACE) meeting.

Clinical experts consulted by the SMC considered that carfilzomib plus dexamethasone is a therapeutic advance as it provides an opportunity to increase overall and progression-free survival when compared to bortezomib plus dexamethasone; one of the current standards of care for relapsed multiple myeloma. It also concluded that carfilzomib is associated with a reduced rate of peripheral neuropathy.

Stock Performance

On Friday, August 11, 2017, the stock closed the trading session at $169.43, slightly climbing 0.19% from its previous closing price of $169.11. A total volume of 1.57 million shareshave exchanged hands. Amgen's stock price advanced 5.75% in the last three months and 0.92% in the past six months. Furthermore, since the start of the year, shares of the Company have surged 15.88%. The stock is trading at a PE ratio of 15.41 and has a dividend yield of 2.71%. At Friday's closing price, the stock's net capitalization stands at $124.36 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily